Sotorasib is a synthetic compound used as an active pharmaceutical ingredient. It acts as an inhibitor of the RAS GTPase family and is investigated for its role in targeting the G12C mutation in the KRAS protein associated with certain cancers.
İçerik kapsamı: Bu sayfadaki bilgiler kimyasal tanımlama ile endüstriyel tedarik, araştırma ve üretim bağlamlarına ilişkindir. Tedavi iddiası, tıbbi tavsiye veya ilaç kullanım talimatı niteliği taşımaz.
Bu bileşiği tedarik ediyor veya sağlıyor musunuz?
Envanterinizi listeleyin veya satın alma talebi gönderin
CAS 2296729-00-3
Sotorasib
active pharmaceutical ingredient
(11alpha,13E)-11-hydroxy-9,15-dioxoprost-13-en-1-oic acid
prostaglandin active pharmaceutical ingredient
Riociguat metabolite M3
active pharmaceutical ingredient metabolite
Atazanavir sulfate
active pharmaceutical ingredient
Terbutaline
beta-adrenergic agonist bronchodilator
6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-yl-3-pyridinyl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one
NXQKSXLFSAEQCZ-SFHVURJKSA-N
C[C@H]1CN(CCN1C2=NC(=O)N(C3=NC(=C(C=C32)F)C4=C(C=CC=C4F)O)C5=C(C=CN=C5C(C)C)C)C(=O)C=C